Şencan, İrfanŞahin, İdrisÖzçetin, Adnan2021-06-232021-06-2320031682-024Xhttps://hdl.handle.net/20.500.12491/4551https://www.scopus.com/inward/record.uri?eid=2-s2.0-0141782621&partnerID=40&md5=56287dc412fcffea225621312dce50f8Toxic hepatitis is observed with high doses of Venlafaxine. But toxic hepatitis has not been yet reported at tower doses of Venlafaxine such as 37.5 mg per day. In this case report, a case of Venlafaxine-associated toxic hepatitis with tower doses in patient with history of chronic hepatitis is presented. We suggest that liver function should be regularly monitored in patients with history of chronic hepatitis receiving Ventafaxine even at tower doses and even when their liver enzymes are normal.eninfo:eu-repo/semantics/closedAccessChronic HepatitisToxic HepatitisVentafaxineArticle1932282292-s2.0-0141782621Q3